Validation of a Longitudinal Marker as a Surrogate Using Mediation Analysis and Joint Modeling: Evolution of the PSA as a Surrogate of the Disease-Free Survival
{{output}}
Longitudinal biomarkers constitute a broad class of potential surrogate endpoints in clinical trials. Several approaches have been proposed for surrogate validation but available methods for validating a longitudinal biomarker as a surrogate of a time-to-event... ...
